Almac secures grant to scale COVID-19 drug production

By Jenni Spinner contact

- Last updated on GMT

(selvanegra/iStock via Getty Images Plus)
(selvanegra/iStock via Getty Images Plus)

Related tags: Almac group, COVID-19, Coronavirus, API, Novartis, Merck

The company has received a $500,000 grant from the COVID-19 Therapeutics Accelerator to develop manufacturing processes for the antiviral drug remdesivir.

Almac Sciences, a member of the Almac Group, has received a $500,000 grant from the COVID-19 Therapeutics Accelerator. The funding is intended to go toward development of cost-effective, scalable processes for producing the active pharmaceutical ingredient (API) of the drug remdesivir.

Remdesivir is the first drug to receive the US Food and Drug Administration’s (FDA) approval as a treatment for COVID-19​.  With the help of the grant funding, Almac Sciences plans to improve the overall route of synthesis, in order to lower raw material usage, increase global yields and lower the overall cost of goods in development.

An Almac Group spokesperson told Outsourcing-Pharma that the grant is the latest in a list of partnerships with various global pharmaceutical, biotech and research institutions that support crucial research projects into COVID-19 treatment options. 

The Group is supporting this urgent research need through a range of service areas, including analytical services, peptide development, expedited Interactive Response Technology (IRT) support and clinical trial manufacturing, packaging and distribution​,” they said.

Stefan Mix, head of biocatalysis with Almac Sciences, said the company welcomes the opportunity to help in the battle against COVID-19.

With the skillset of our multidisciplinary teams, we are confident that our developmental approach to the manufacture of remdesivir will positively impact patients’ lives who in urgent need, regardless of their location​,” he said.

This project highlights Almac’s strength in technology deployment through application of both innovative flow chemistry and biocatalysis technologies to support development of processes which are economical, greener and safer to perform,​” added Tom Moody, vice president of technology development and commercialization with Almac Sciences and Arran Chemical.

The COVID-19 Therapeutics Accelerator is a collaborative project backed by the Bill & Melinda Gates Foundation, Wellcome and Mastercard​, with funding funneled from a broad range of public and philanthropic donors. The project brings together life-sciences professionals from a variety of organizations (including pharmaceutical firms such as Merck, Novartis, GSK and others) to help bolster global response to the COVID-19 pandemic by funding the identification, assessment, development and scale up of treatments.

Related news

Show more

Related products

show more

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars